Publications by authors named "J M Laborde"
Introduction: Total pelvic exenteration (TPE) for clinical T4b colorectal cancer (CRC) is associated with significant morbidity. Short (0-30 days)- and intermediate (31-90 days)-term temporal analysis of complication onset is not well described, yet needed, to better counsel patients considering TPE.
Methods: A retrospective cohort study of consecutive patients with primary or recurrent clinical T4b pelvic CRC undergoing open TPE between 2014 and 2023 was conducted.
Article Synopsis
- - A Phase II trial was conducted to evaluate the combination of gemcitabine and nab-paclitaxel for treating recurrent osteosarcoma in patients aged 12-30, with an emphasis on assessing progression-free survival and identifying potential biomarkers.
- - Eighteen patients participated, showing a 28% progression-free survival rate after four months, with some experiencing partial responses but facing dose reductions and toxicities.
- - The study concluded that the gemcitabine and nab-paclitaxel combination has comparable effectiveness and toxicity to previous treatments with gemcitabine and docetaxel, while highlighting the potential for using circulating tumor cells and circulating tumor DNA as response biomarkers in future research.
Background: Uveal melanoma often metastasizes to the liver, portending a poor prognosis. Melphalan/hepatic delivery system (HDS) via percutaneous hepatic perfusion (PHP) is a minimally invasive means of circulating high-dose chemotherapy through the affected liver. This study evaluated melphalan/HDS use as either first-line or second-line treatment to guide treatment sequencing.
View Article and Find Full Text PDFArticle Synopsis
- A study assessed the predictive value of blood-tumor mutational burden (bTMB) against microsatellite instability-high (MSI-H) in patients with advanced GI tumors receiving immune checkpoint inhibitors (ICIs).
- It compared two groups: patients with bTMB-high tumors (MSS-bTMB-H) and those with MSI-H, analyzing outcomes like overall response rate (ORR) and progression-free survival (PFS).
- Results indicated that the MSI-H group had significantly better treatment outcomes than the MSS-bTMB-H group, suggesting that bTMB-H may not be a reliable predictive biomarker for treatment efficacy in these tumors.